These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3838399)

  • 1. Pharmacokinetics of molsidomine in humans.
    Ostrowski J; Resag K
    Am Heart J; 1985 Mar; 109(3 Pt 2):641-3. PubMed ID: 3838399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T; Brandstätter A; Trenk D; Jähnchen E; Ostrowski J; Gärtner W
    Am Heart J; 1985 Mar; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human pharmacokinetics of molsidomine].
    Singlas E; Martre H
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):503-9. PubMed ID: 6364946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
    Ostrowski J; Gaul G; Voegele D; Brockmeier D; Resag K
    Eur J Clin Pharmacol; 1985; 28(5):611-3. PubMed ID: 3899679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
    Bergstrand R; Vedin A; Wilhelmsson C; Peterson LE; Chamberlain J; Dell D; Stevens LA; Ostrowski J
    Eur J Clin Pharmacol; 1984; 27(2):203-8. PubMed ID: 6548711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].
    Schulz W; Wendt T; Scherer D; Kober G
    Z Kardiol; 1983 Jul; 72(7):404-9. PubMed ID: 6613236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption and disposition of [14C]-molsidomine in laboratory animals.
    Fromson JM; Illing HP; Ings RM; Johnson KI; Johnson P; Ostrowski J; Schraven E; Steward A
    Arzneimittelforschung; 1981; 31(2):337-45. PubMed ID: 6894378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog.
    Fiedler VB; Göbel H; Nitz RE
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):56-75. PubMed ID: 6409016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of sustained-release capsules of molsidomine (SIN-10) in dogs and monkeys.
    Morimoto M; Yamashita K; Koyama H; Fujimoto H; Toguchi H; Kitamori N
    Chem Pharm Bull (Tokyo); 1986 Mar; 34(3):1257-63. PubMed ID: 3755382
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of repeated intravenous and oral doses of molsidomine (N-carboxy-3-morpholino-sydnonimine-ethylester) on plasma renin activity and plasma catecholamine levels in conscious dogs.
    Bacher S; Kraupp O; Stanek B; Raberger G
    Basic Res Cardiol; 1983; 78(2):193-202. PubMed ID: 6347175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-ischemic effect of 8 mg molsidomin in retard form].
    Blasini R; Brügmann U; Rudolph W
    Herz; 1984 Dec; 9(6):346-52. PubMed ID: 6392050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ergometric study of a new vasodilator agent in angina: molsidomine. Value of combination with beta-blockaders].
    Witchitz S; Kolsky H; Moisson P; Valette H
    Arch Mal Coeur Vaiss; 1981 Apr; 74(4):463-71. PubMed ID: 6112971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.
    Sobolski J; Vandermoten P; Stoupel E; Berkenboom G; Degre S
    Am Heart J; 1985 Mar; 109(3 Pt 2):700-3. PubMed ID: 3838407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of metoprolol with molsidomine in the treatment of angina pectoris.
    van Mantgem JP; Lie KI; Matroos AW
    Eur J Clin Pharmacol; 1985; 28(2):109-11. PubMed ID: 3838725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molsidomin in coronary disease. Clinico-pharmacokinetic correlation study on the effect of oral and sublingual therapy].
    Strasser R; Klepzig H; Ostrowski J; Resag K
    MMW Munch Med Wochenschr; 1983 Feb; 125(8):156-8. PubMed ID: 6405248
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of molsidomine on coronary collateral blood flow in acute myocardial ischemia.
    Gross GJ; Gharaibeh M
    Eur J Pharmacol; 1980 Oct; 67(1):111-4. PubMed ID: 6893436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological basis of therapy with molsidomine].
    Bassenge E
    Herz; 1982 Oct; 7(5):296-306. PubMed ID: 6897544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
    Fach WA; Becker HJ
    Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic effects of molsidomine in patients with severe chronic coronary disease.
    Crexells C; Lidón RM; Augé JM; Bosch X; Pina C; Garcia J; Oriol A
    Eur Heart J; 1985 Dec; 6(12):1032-9. PubMed ID: 3841658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.